Related Experiment Video

Updated: Jun 26, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Improvement of chemotherapy efficacy by inactivation of a DNA-repair pathway

Mark R Middleton1, Geoffrey P Margison

  • 1Cancer Research UK Medical Oncology Unit, Churchill Hospital, Oxford, UK.

The Lancet. Oncology
|January 9, 2003
PubMed

Insights

Inhibiting the DNA repair enzyme O6-alkylguanine-DNA alkyltransferase (ATase) can reverse tumour resistance to alkylating agents. However, inactivating ATase in normal tissues limits therapeutic effectiveness due to toxicity.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Chemotherapeutic drug efficacy is often limited by tumour resistance and dose-limiting toxic effects.
  • Alkylating agents are a class of chemotherapeutics used in cancer treatment.
  • O6-alkylguanine-DNA alkyltransferase (ATase) is a DNA repair protein conferring cellular resistance to certain alkylating agents.

Purpose of the Study:

  • To investigate the role of ATase in tumour resistance to alkylating agents.
  • To evaluate the potential of ATase inactivation as a strategy to enhance chemotherapy effectiveness.
  • To assess the impact of ATase inactivation in normal tissues on therapeutic outcomes.

Main Methods:

  • Review of in vitro and in vivo experimental data on ATase function and inactivation.
  • Analysis of clinical trial results for drugs targeting ATase.
  • Examination of the balance between tumour ATase inactivation and normal tissue toxicity.

Main Results:

  • ATase inactivation has been shown to reverse tumour resistance to specific alkylating agents.
  • Clinical trials indicate that ATase-inactivating drugs exhibit activity in tumour tissues.
  • Inactivation of ATase in normal tissues, such as bone marrow, leads to toxicity, necessitating reduced alkylating agent dosage.

Conclusions:

  • While ATase inactivation can overcome tumour resistance, its concurrent inactivation in normal tissues poses a significant challenge.
  • The current lack of tumour-specific delivery strategies for ATase inhibitors raises questions about their overall therapeutic benefit.
  • Further research is needed to develop strategies that selectively target tumour ATase to improve the therapeutic ratio of alkylating agents.

More Related Videos

Evaluating In Vitro DNA Damage Using Comet Assay10:43

Evaluating In Vitro DNA Damage Using Comet Assay

Published on: October 11, 2017

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays04:07

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

Related Concept Videos

Overview of DNA Repair02:25

Overview of DNA Repair

In order to be passed through generations, genomic DNA must be undamaged and error-free. However, every day, DNA in a cell undergoes several thousand to a million damaging events by natural causes and external factors. Ionizing radiation such as UV rays, free radicals produced during cellular respiration, and hydrolytic damage from metabolic reactions can alter the structure of DNA. Damages caused include single-base alteration, base dimerization, chain breaks, and cross-linkage.
Chemically...
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Overview of DNA Repair02:25

Overview of DNA Repair

In order to be passed through generations, genomic DNA must be undamaged and error-free. However, every day, DNA in a cell undergoes several thousand to a million damaging events by natural causes and external factors. Ionizing radiation such as UV rays, free radicals produced during cellular respiration, and hydrolytic damage from metabolic reactions can alter the structure of DNA. Damages caused include single-base alteration, base dimerization, chain breaks, and cross-linkage.
Chemically...
Nucleotide Excision Repair01:38

Nucleotide Excision Repair

DNA Distortion and Damage
Cells are regularly exposed to mutagens—factors in the environment that can damage DNA and generate mutations. UV radiation is one of the most common mutagens and is estimated to introduce a significant number of changes in DNA. These include bends or kinks in the structure, which can block DNA replication or transcription. If these errors are not fixed, the damage can cause mutations, which in turn can result in cancer or disease depending on which sequences are...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...